Literature DB >> 2594368

High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.

I Bongarzone1, M A Pierotti, N Monzini, P Mondellini, G Manenti, R Donghi, S Pilotti, M Grieco, M Santoro, A Fusco.   

Abstract

We had previously detected a transforming oncogene, designated PTC, in 25% of 20 papillary thyroid carcinomas. In order to characterize further the transforming activity of this tumour histotype, a new panel of tumour specimens from 16 patients was analysed by using a modified calcium phosphate-DNA coprecipitation transfection protocol. Tumour DNA from 10 patients (62%) displayed a transforming activity due to activation of three different oncogenes identified in four cases as PTC, in four cases as TRK, and in two cases as N-RAS. The same structural alterations of PTC and TRK (gene rearrangements) as well as of N-RAS (point mutation) detected in the NIH3T3 transformants, were also found in the original tumour DNAs, thus indicating that their activation was not due to transfection procedures. Since both PTC, a novel rearranged form of RET, and TRK display a tyrosine protein kinase activity, it is proposed that the activation of this class of oncogenes is specifically involved in the pathogenesis of papillary thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594368

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  72 in total

1.  An STS in the human PTC oncogene located at 10q11.2.

Authors:  S M Jhiang; I M Chiu; E L Mazzaferri
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

2.  Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

Authors:  I Bongarzone; N Monzini; M G Borrello; C Carcano; G Ferraresi; E Arighi; P Mondellini; G Della Porta; M A Pierotti
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

Review 3.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

4.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

5.  Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.

Authors:  L V Owens; L Xu; G A Dent; X Yang; G C Sturge; R J Craven; W G Cance
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

6.  Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels.

Authors:  H-U G Weier; J Kwan; C-M Lu; Y Ito; M Wang; A Baumgartner; S W Hayward; J F Weier; H F Zitzelsberger
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

7.  Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.

Authors:  M A Pierotti; M Santoro; R B Jenkins; G Sozzi; I Bongarzone; M Grieco; N Monzini; M Miozzo; M A Herrmann; A Fusco
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

8.  Role of STAT3 in in vitro transformation triggered by TRK oncogenes.

Authors:  Claudia Miranda; Tiziana Fumagalli; Maria Chiara Anania; Maria Grazia Vizioli; Sonia Pagliardini; Marco A Pierotti; Angela Greco
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

Review 9.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Authors:  Alison M Schram; Matthew T Chang; Philip Jonsson; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

10.  A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2.

Authors:  F Canzian; P Amati; H R Harach; J L Kraimps; F Lesueur; J Barbier; P Levillain; G Romeo; D Bonneau
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.